CYBIN (formerly Clarmin Explorations Inc.), a life sciences company initially focused on psychedelic pharmaceutical therapies, on Thursday announced it has completed its previously disclosed reverse takeover of Clarmin Explorations Inc. per the terms of an amalgamation agreement dated June 26, 2020, as amended on October 21, 2020. The agreement was among Cybin Corp., Clarmin and 2762898 Ontario Inc. (“SubCo”), a wholly-owned subsidiary of the company (the “reverse takeover”), in which the reverse takeover was completed by way of a “three-cornered” amalgamation pursuant to the provisions of the Business Corporations Act (Ontario). Through the reverse takeover, Cybin Corp. amalgamated with SubCo to form an amalgamated corporation and a wholly owned subsidiary of the company. The company now focuses on the business of Cybin Corp., which includes psychedelic drug development, unique delivery mechanisms, improved novel compounds and protocols that target psychiatric and neurological conditions. “We are very pleased to have completed the reverse takeover and to have received conditional approval to list CYBIN’s shares on the NEO Exchange. We anticipate it will help us to enhance our visibility within the investment community and broaden our investor base, with the goal of building long-term shareholder value. It also represents an important step forward in advancing our development plans,” said Doug Drysdale, CYBIN’s chief executive officer. “We believe in the application of psychedelic therapies and look forward to advancing them and our other product candidates.”
To view the full press release, visit https://ibn.fm/vLDVj
About CYBIN Inc.
CYBIN is a life sciences company advancing psychedelic pharmaceutical treatments for various psychiatric and neurological conditions. CYBIN is developing technologies and delivery systems aiming to improve bioavailability to achieve the desired effects of psychedelics at low dosage levels. The new delivery systems are expected to be studied through clinical trials to confirm safety and efficacy. For more information, visit the company’s website at www.CYBIN.com.
NOTE TO INVESTORS: The latest news and updates relating to CYBIN are available in the company’s newsroom at http://ibn.fm/Cybin
PsychedelicNewsWire (PNW) is a specialized content distribution company that (1) aggregates and distributes news and information on the latest developments in all aspects and advances of psychedelics and their use, (2) creates PsychedelicNewsBreaks designed to quickly update investors on important industry news, (3) leverages a team of expert editors to enhance press releases for maximum impact, (4) assists companies with the management and optimization of social media across a range of platforms, and (5) delivers unparalleled corporate communication solutions. PNW stays abreast of the latest information and has established a reputation as the go to source for coverage of psychedelics, therapeutics and emerging market opportunities. Our team of seasoned journalists has a proven track record of helping both public and private companies gain traction with a wide audience of investors, consumers, media outlets and the general public by leveraging our expansive dissemination network of more than 5,000 key syndication outlets. PNW is committed to delivering improved visibility and brand recognition to companies operating in the emerging markets of psychedelics.
To receive instant SMS alerts, text “Groovy” to 21000 (U.S. Mobile Phones Only)
For more information please visit https://www.PsychedelicNewsWire.com
Do you have questions or are you interested in working with PNW? Ask our Editor
PsychedelicNewsWire is part of the InvestorBrandNetwork.